Werewolf Therapeutics to acquire Ambros Therapeutics in a stock merger

Werewolf Therapeutics announced a definitive agreement to acquire Ambros Therapeutics via a stock-for-stock merger. The deal, valued at over $132 million, aims to combine Werewolf's platform with Ambros's dual lead assets and is expected to expand Werewolf's intellectual property portfolio and clinical pipeline.